An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

NCT07161700 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder (MDD)
Major Depressive Disorder With Anxious Distress

Interventions

DRUG: SPT-300

Sponsor

Seaport Therapeutics

Collaborators

[object Object]